Associated Papers
Pharmacogenetics of First-Line Antitubercular Drugs: An Update.
Manca A et al.
Therapeutic Drug Monitoring, 2026
Pharmacogenomics and mutation informatics: correlation of NAT2 mutations and isoniazid acetylation rate.
Verma S et al.
Drug Discovery Today, 2026
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Direct Comparative Analysis of a Pharmacogenomics Panel with PacBio Hifi® Long-Read and Illumina Short-Read Sequencing.
Barthélémy D et al.
Journal of Personalized Medicine, 2023
Gene Polymorphism of Biotransformation Enzymes and Ciprofloxacin Pharmacokinetics in Pediatric Patients with Cystic Fibrosis.
Zyryanov SK et al.
Biomedicines, 2022
Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review.
Hein DW et al.
Expert Opinion on Drug Metabolism & Toxicology, 2021
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Distribution and Role of N-acetyltransferase 2 Genetic Polymorphisms in Bladder Cancer Risk in a Lebanese Population
Nasr R et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2017
Arylamine N-acetyltransferase 2 gene polymorphism in an Algerian population.
Chelouti H et al.
Annals of Human Biology, 2017
Catalytic properties and heat stabilities of novel recombinant human N-acetyltransferase 2 allozymes support existence of genetic heterogeneity within the slow acetylator phenotype.
Hein DW et al.
Archives of Toxicology, 2017
N-acetyltransferase 2 (NAT2) gene polymorphism as a predisposing factor for phenytoin intoxication in tuberculous meningitis or tuberculoma patients having seizures - A pilot study.
Adole PS et al.
The Indian Journal of Medical Research, 2016
N-Acetyltransferase 2 (NAT2) polymorphism as a risk modifier of susceptibility to pediatric acute lymphoblastic leukemia.
Kamel AM et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine, 2015
Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.
Sim E et al.
British Journal of Pharmacology, 2014
NAT2, XRCC1 and hOGG1 polymorphisms, cigarette smoking, alcohol consumption and risk of upper aerodigestive tract cancer.
Marques CR et al.
Anticancer Research, 2014
A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?
Baietto L et al.
Current Drug Metabolism, 2014
Full-gene-sequencing analysis of N-acetyltransferase-2 in an adult Indian population.
Tilak AV et al.
Genetic Testing and Molecular Biomarkers, 2013
Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients.
Zabost A et al.
Biomed Research International, 2013
Study of NAT2 genetic polymorphism in West African subjects: example of an healthy non-smoker Senegalese population.
Touré A et al.
Molecular Biology Reports, 2012
Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs.
Costa GN et al.
Molecular Diagnosis & Therapy, 2012
Genetic polymorphism of NAT2 metabolizing enzymes on phenytoin pharmacokinetics in Indian epileptic patients developing toxicity.
Murali M et al.
Cns Neuroscience & Therapeutics, 2012
Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes.
Hein DW et al.
Pharmacogenomics, 2012
Acetylator status and N-acetyltransferase 2 gene polymorphisms; phenotype-genotype correlation with the sulfamethazine test.
Taja-Chayeb L et al.
Pharmacogenetics and Genomics, 2011
N-Acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in Serbs: unprecedented high prevalence of rapid acetylators in a White population.
Djordjevic N et al.
Journal of Clinical Pharmacology, 2011
Effects of single nucleotide polymorphisms on human N-acetyltransferase 2 structure and dynamics by molecular dynamics simulation.
Rajasekaran M et al.
Plos One, 2011
Phenotype prediction of nonsynonymous single nucleotide polymorphisms in human phase II drug/xenobiotic metabolizing enzymes: perspectives on molecular evolution.
Hao D et al.
Science China. Life Sciences, 2010
Combined effect of CYP1B1 codon 432 polymorphism and N-acetyltransferase 2 slow acetylator phenotypes in relation to breast cancer in the Turkish population.
Ozbek YK et al.
Anticancer Research, 2010
Polymorphisms in NAT2 gene and atherosclerosis in an Algerian population.
Khelil M et al.
Archives of Medical Research, 2010
Sequence analysis of NAT2 gene in Brazilians: identification of undescribed single nucleotide polymorphisms and molecular modeling of the N-acetyltransferase 2 protein structure.
Teixeira RL et al.
Mutation Research, 2010
Comparison of genetic polymorphisms of the NAT2 gene between Korean and four other ethnic groups.
Kang TS et al.
Journal of Clinical Pharmacy and Therapeutics, 2009
N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine.
Hein DW
Expert Opinion on Drug Metabolism & Toxicology, 2009
Study of NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients.
Singh N et al.
Molecular Diagnosis & Therapy, 2009
Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity.
Walker K et al.
Journal of Toxicology and Environmental Health. Part B, Critical Reviews, 2009
Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2.
Walraven JM et al.
Current Drug Metabolism, 2008
Genotyping panel for assessing response to cancer chemotherapy.
Dai Z et al.
Bmc Medical Genomics, 2008
Arylamine N-acetyltransferases: from structure to function.
Sim E et al.
Drug Metabolism Reviews, 2008
Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases.
Wu H et al.
The Journal of Biological Chemistry, 2007
Polymorphism of selected enzymes involved in detoxification and biotransformation in relation to lung cancer.
Gresner P et al.
Lung Cancer (amsterdam, Netherlands), 2007
Genetic polymorphism in bladder cancer.
Wu X et al.
Frontiers in Bioscience : a Journal and Virtual Library, 2007
[Detection of mutation in NAT II gene as a method of determination of izoniazyd (INH) acetylation type in human population].
Augustynowicz-Kopeć E et al.
Pneumonologia I Alergologia Polska, 2007
Effects of single nucleotide polymorphisms in human N-acetyltransferase 2 on metabolic activation (O-acetylation) of heterocyclic amine carcinogens.
Hein DW et al.
International Journal of Cancer, 2006
[Comparative analysis of N-acetylation polymorphism in humans as determined by phenotyping and genotyping].
Goldenkova-Pavlova IV et al.
Genetika, 2006
Discordance between N-acetyltransferase 2 phenotype and genotype in a population of Hmong subjects.
Straka RJ et al.
Journal of Clinical Pharmacology, 2006
Arylamine N-acetyltransferase gene polymorphisms: markers for atopic asthma, serum IgE and blood eosinophil counts.
Batra J et al.
Pharmacogenomics, 2006
Simultaneous determination of 7 N-acetyltransferase-2 single-nucleotide variations by allele-specific primer extension assay.
Zhu Y et al.
Clinical Chemistry, 2006
N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk.
Hein DW
Oncogene, 2006
Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
Bosch TM et al.
Clinical Pharmacokinetics, 2006
Crohn's disease in Japanese is associated with a SNP-haplotype of N-acetyltransferase 2 gene.
Machida H et al.
World Journal of Gastroenterology, 2005
'Comparison of extremes' approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility.
Belogubova EV et al.
Cancer Letters, 2005
Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic sclerosis.
Skretkowicz K et al.
European Journal of Clinical Pharmacology, 2005
An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore.
Chowbay B et al.
Drug Metabolism Reviews, 2005